UroGen Pharma Ltd. (LON: 0XOD)
London
· Delayed Price · Currency is GBP · Price in USD
10.06
-0.30 (-2.90%)
At close: Jan 22, 2025
UroGen Pharma Revenue
UroGen Pharma had revenue of $25.20M USD in the quarter ending September 30, 2024, with 20.87% growth. This brings the company's revenue in the last twelve months to $89.36M, up 15.64% year-over-year. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.
Revenue (ttm)
$89.36M
Revenue Growth
+15.64%
P/S Ratio
n/a
Revenue / Employee
$444.59K
Employees
201
Market Cap
344.35M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Shell | 221.41B |
AstraZeneca | 38.20B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
BP p.l.c. | 144.69B |
British American Tobacco p.l.c. | 26.18B |